Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Small Cell Lung Cancer, Combined Type”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03319459
What this trial is testing

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Who this might be right for
HER2 Positive Gastric CancerColorectal CancerHead and Neck Squamous Cell Carcinoma+8 more
Fate Therapeutics 44
Early research (Phase 1)Study completedNCT00966472
What this trial is testing

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Who this might be right for
Squamous Cell CarcinomaNon-Small Cell Lung Cancer
Ottawa Hospital Research Institute 24
Testing effectiveness (Phase 2)UnknownNCT04124731
What this trial is testing

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Who this might be right for
CarcinomaNon-small Cell Lung Cancer
Shanghai Chest Hospital 98
Testing effectiveness (Phase 2)Study completedNCT00436332
What this trial is testing

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Who this might be right for
Lung Cancer
SWOG Cancer Research Network 84
Testing effectiveness (Phase 2)UnknownNCT02738983
What this trial is testing

RT Plus EGFR-TKI for Wild-type NSCLC

Who this might be right for
Non-small Cell Lung CancerEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)
Hangzhou Cancer Hospital 22
Large-scale testing (Phase 3)Ended earlyNCT02134015
What this trial is testing

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
Daiichi Sankyo 145
Testing effectiveness (Phase 2)Looking for participantsNCT05024214
What this trial is testing

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Who this might be right for
Solid TumorsNon-small Cell Lung CancerRenal Cell Carcinoma+1 more
3D Medicines (Sichuan) Co., Ltd. 170
Testing effectiveness (Phase 2)UnknownNCT05094804
What this trial is testing

OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Who this might be right for
CancerTumor, SolidMalignant Neoplasm+7 more
OncoResponse, Inc. 172
Testing effectiveness (Phase 2)Study completedNCT00563784
What this trial is testing

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung CancerLung Cancer
M.D. Anderson Cancer Center 68
Testing effectiveness (Phase 2)Study completedNCT03674567
What this trial is testing

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Who this might be right for
Advanced Cancer
RAPT Therapeutics, Inc., a member of the GSK plc group of companies 323
Early research (Phase 1)Study completedNCT05585034
What this trial is testing

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more
Xencor, Inc. 60
Early research (Phase 1)Ended earlyNCT06974734
What this trial is testing

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Who this might be right for
Carcinoma, Non Small Cell LungCarcinoma, Pancreatic DuctalMalignant Melanoma+1 more
Pfizer 8
Large-scale testing (Phase 3)Ended earlyNCT00673049
What this trial is testing

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Who this might be right for
Carcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell+1 more
Pfizer 583
Early research (Phase 1)Study completedNCT00655655
What this trial is testing

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Who this might be right for
GastrinomaGlucagonomaInsulinoma+17 more
Mayo Clinic 96
Testing effectiveness (Phase 2)Looking for participantsNCT07730021
What this trial is testing

ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Astellas Pharma Global Development, Inc. 392
Early research (Phase 1)Looking for participantsNCT06270706
What this trial is testing

PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumor
Pliant Therapeutics, Inc. 124
Testing effectiveness (Phase 2)Looking for participantsNCT07038096
What this trial is testing

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Who this might be right for
Small Cell Lung CancerNeuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 350
Testing effectiveness (Phase 2)UnknownNCT03715985
What this trial is testing

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

Who this might be right for
Malignant Melanoma, MetastaticNon Small Cell Lung Cancer MetastaticBladder Urothelial Carcinoma, Metastatic
Herlev Hospital 12
Early research (Phase 1)Study completedNCT02185690
What this trial is testing

A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

Who this might be right for
Lungcancer
University Health Network, Toronto 13
Early research (Phase 1)Study completedNCT06894771
What this trial is testing

MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 5
Next Page